Lentogest

Hydroxyprogesterone caproate, the active ingredient in Lentogest, is a progestogen presented as an injectable solution for intramuscular use. It is employed to lower the risk of preterm birth in pregnant women identified as being at increased risk. It is authorized in the European Union for this indication and is supplied as a sterile, preservative‑free solution.

GNH USA supplies Lentogest as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with a focus on quality assurance and regulatory compliance.

Hydroxyprogesterone caproate is a progestogen used in the management of pregnancy‑related uterine activity.

- Prevention of preterm birth: reduces the incidence of early delivery in pregnant women at risk. - History of spontaneous preterm delivery: lowers recurrence risk in subsequent pregnancies. - Short cervical length or other high‑risk obstetric factors: supports uterine quiescence and may decrease preterm labor incidence.

Adverse reactions reported with intramuscular hydroxyprogesterone caproate include the following.

Common Side Effects: - Injection site pain: mild to moderate discomfort at the administration site. - Local erythema or swelling: transient redness or puffiness. - Headache: occasional mild headache. - Nausea: occasional mild nausea.

Serious or Rare Side Effects: - Allergic reaction: rash, itching, or anaphylaxis in susceptible individuals. - Thromboembolic events: rare cases of deep vein thrombosis. - Hepatotoxicity: abnormal liver function tests reported rarely.

When using Lentogest, consider the following precautions.

- Pregnancy: use only when the expected benefit justifies potential risk. - Breastfeeding: safety not established; weigh maternal benefit against infant exposure. - Allergy: avoid if hypersensitivity to hydroxyprogesterone caproate or formulation excipients is known. - Liver disease: monitor hepatic function as metabolism may be impaired. - Concomitant hormonal therapy: assess for additive progestogenic effects. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Hydroxyprogesterone caproate may interact with other medicines as follows.

Major Interactions (Avoid): - Concurrent progestogenic agents: may increase overall progestogenic activity. - Estrogen‑containing contraceptives: potential additive hormonal effects.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole): may raise plasma concentrations. - CYP3A4 inducers (e.g., rifampin): may reduce therapeutic effectiveness. - Anticoagulants (e.g., warfarin): monitor coagulation parameters for altered bleeding risk.